TP53, tumor protein p53, 7157

N. diseases: 2494; N. variants: 527
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group CLINVAR
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE <b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). 31157548 2019
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE 20 of the 32 (69%) NSCLC patients contained mutant P53 in the yeast functional assay with the higher frequency in squamous cell carcinoma (14/17, 82%) than in adenocarcinoma (5/10, 50%) and large cell carcinoma (3/5, 60%) (p<0.01, chi2 test). 11374799 2001
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE 46/103 (44.6%) NSCLC showed p53 mutations and 17/103 (16.5%) c-Ki-ras mutations including 12/37 (32.4%) adenocarcinomas. 10945494 2000
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. 8020801 1994
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE TP53 mutations were found in 47 of 94 primary tumors (50%), and K-ras mutations were present in 26 of 55 adenocarcinomas (47%). 11882817 2002
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group LHGDN TP53 and SMAD4 status were determined by immunohistochemistry on tissue microarrays of 23 archival familial pancreatic adenocarcinomas and in selected cases by cycle sequencing to identify TP53 gene mutations. 19064568 2008
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE TP53 mutation positive status was most common in adenocarcinoma (OR 2.0, 95% CI, 1.1-3.7; compared with squamous cell carcinoma), and mutation positivity showed an overall, nonsignificant association with wood-dust exposure (OR 1.6, 95% CI, 0.8-3.1). 19950227 2010
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE TP53 mutations were detected in 48.8% of cases and were more frequent among SCCs than ADCs (p<0.0001). 22267755 2012
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE TP53 mutations were identified in 9.1% of intermediate-grade IPMNs (2 of 22), 17.8% of PanIN-2 (8 of 45), 38.1% of high-grade IPMNs (8 of 21), 47.6% of PanIN-3 (10 of 21), and 75% of invasive pancreatic adenocarcinomas (15 of 20); no TP53 mutations were found in PanIN-1 lesions or low-grade IPMNs. 23200980 2013
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE TP53 mutations were observed exclusively in four adenocarcinoma components, consistent with their role in the progression from adenoma to adenocarcinoma. 24470207 2014
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration. 10928127 2000
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group CTD_mouse A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. 16247444 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE A total of 297 resected Japanese non-small cell lung cancers (74 squamous cell carcinomas and 223 adenocarcinomas) were analyzed to evaluate the validity of the p53 mutation spectrum as a fingerprint for mutagenic substances as etiological factors. 18271927 2008
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Aberrant p53 protein accumulation was measured immunohistologically in 342 colorectal paraffin-embedded tissue sections from 115 patients (24 with adenocarcinoma, 59 with adenoma and 32 'hospital controls'). 12944180 2004
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Aberrant methylations of p16INK4a and p14ARF gene were present in 21 (32.3%) and 33 (50.8%) out of 65 cases, respectively. p16INK4a aberrant methylation was correlated with p16 negativity (P=0.021) and p53 overexpression (P=0.007). p16INK4a aberrant methylation was more frequently present in poorly differentiated adenocarcinomas (P=0.002). 16675157 2006
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Abnormalities involving the p16 (also known as cyclin-dependent kinase N2 [CDKN2], p16 [INK4a], or MTS1) and p53 (also known as TP53) tumor suppressor genes are highly prevalent in esophageal adenocarcinomas. 10601379 1999
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Abnormalities of the tumour suppressor gene p53 have been shown in approximately 60% of advanced gastric adenocarcinomas and it has been suggested that the immunohistochemical finding of increased p53 expression is a prognostic marker in gastric cancer. 7829004 1994
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE According to the analysis, typical EBV-associated gastric adenocarcinoma constitutes an independent molecular pathological subgroup, which is mutually exclusive to TP53-mutated adenocarcinoma with chromosomal instability, another molecular pathological subtype in gastric adenocarcinomas. 26617924 2015
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 GeneticVariation group BEFREE Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. 12796380 2003
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Allelic imbalances in D3S1283, D3S1234, D3S1300, D3S1285, TP53, D17S938, and D9S179 were less frequent in SH than in adenocarcinoma; rates of allelic imbalances in D20S170 and D21S1446 were not significantly different. 21649526 2011
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 Biomarker group BEFREE Alterations in tumor suppressor genes, amongst which p53 and p16, are early events in the metaplasia-dysplasia-adenocarcinoma sequence, followed by loss of cell cycle checkpoints. 16299787 2005
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Alterations of APC, KRAS and TP53 were observed in a higher percentage of adenocarcinomas compared to adenomas (P<0.05) indicating that the alterations accumulated with malignancy. 19576232 2009
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Alterations of the retinoblastoma (Rb) gene were evaluated in nine primary endometrial adenocarcinomas that we had previously analyzed for the presence of Ki-ras activations and p53 alterations and in three endometrial carcinoma cell lines. 8105795 1993
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.700 AlteredExpression group BEFREE Altered immunohistochemical detection of c-erbB-2, DF3, B72.3, p53 and Ki-67 was observed with progression and differentiation to two distinct histologic types of invasive carcinoma. c-erbB-2 and DF3 were detected in 50% and 18% of lesions at the stage of atypical hyperplasia and expression increased to 78% and 54% in invasive adenocarcinomas. 9458364 1998